Alemtuzumab (CAMPATH 1-H) therapy in sporadic inclusion body myositis (sIBM) alters disease progression and suppresses endomysial inflammation. - Dalakas,M.C.; Rakocevic,G.; McElroy,B. (Ann Neurol, 2007)